Miller, Robert S. http://orcid.org/0000-0003-0869-6316
Mokiou, Stella
Taylor, Aliki
Sun, Ping
Baria, Katherine
Funding for this research was provided by:
AstraZeneca
Merck Sharp & Dohme Corp.
Article History
Received: 2 December 2021
Accepted: 7 February 2022
First Online: 22 February 2022
Declarations
:
: RM has no competing interests to declare. SM, AR, MJ, PS and KM are employees and/or stockholders of AstraZeneca LP.
: This observational study was performed in accordance with ethical principles that are consistent with the Declaration of Helsinki, International Conference on Harmonisation (ICH) Good Clinical Practice (GCP), Good Pharmacoepidemiology Practice (GPP) and the applicable legislation on non-interventional studies and/or observational studies.
: This research study was conducted retrospectively from CancerLinQ Discovery data obtained for clinical purposes and subsequently de-identified. In 2013, at the request of ASCO, the New England Institutional Review Board determined that the collection of identifiable patient information in CancerLinQ and its subsequent de-identification and reuse for research did not itself constitute research in human participants [CitationRef removed].